Literature DB >> 29317077

The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years.

Nora V Bergasa1.   

Abstract

The pruritus of cholestasis is a maddening complication of liver disease. Increased opioidergic tone contributes to the pruritus of cholestasis, as evidenced by the amelioration of the symptom by opiate antagonists. Obeticholic acid, an agonist of the farnesoid receptor, has been approved for the treatment of primary biliary cholangitis, a disease characterized by cholestasis; this drug is associated with pruritus, the cause of which is unknown. In animal models, bile acids, which accumulate in the body as a result of cholestasis, have been reported to cause scratching behavior mediated by the TGR5 receptor, in an opioid-dependent manner, in laboratory animals. As obeticholic acid also binds to TGR5, the pruritus caused by this drug is likely to be mediated by the opioid system. Lisophosphatidic acid, which has been reported to be increased in patients with cholestasis and pruritus, has been described to cause scratching behavior that is prevented by an opiate antagonist in laboratory animals, suggesting an opioid-receptor mediated mechanism of scratching. In summary, evidence continues to support a role of the endogenous opioid system in the pathogenesis of the pruritus of cholestasis.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29317077     DOI: 10.1016/j.mehy.2017.11.002

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments.

Authors:  Ashley Vander Does; Cynthia Levy; Gil Yosipovitch
Journal:  Am J Clin Dermatol       Date:  2022-07-28       Impact factor: 6.233

2.  Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel.

Authors:  Jennifer Pate; Juilo A Gutierrez; Catherine T Frenette; Aparna Goel; Sonal Kumar; Richard A Manch; Edward A Mena; Paul J Pockros; Sanjaya K Satapathy; Kidist K Yimam; Robert G Gish
Journal:  BMJ Open Gastroenterol       Date:  2019-02-01

Review 3.  Cholestasis-Associated Pruritus and Its Pruritogens.

Authors:  Jacqueline A G M Langedijk; Ulrich H Beuers; Ronald P J Oude Elferink
Journal:  Front Med (Lausanne)       Date:  2021-03-09

4.  Endogenous Opioid Levels Do Not Correlate With Itch Intensity and Therapeutic Interventions in Hepatic Pruritus.

Authors:  Miriam M Düll; Katharina Wolf; Marcel Vetter; Peter Dietrich; Markus F Neurath; Andreas E Kremer
Journal:  Front Med (Lausanne)       Date:  2021-04-14

Review 5.  Pruritus in Pregnancy.

Authors:  Aleksandra A Stefaniak; Manuel P Pereira; Claudia Zeidler; Sonja Ständer
Journal:  Am J Clin Dermatol       Date:  2022-02-21       Impact factor: 7.403

Review 6.  Mechanisms and Management of Itch in Dry Skin.

Authors:  Catharina Sagita Moniaga; Mitsutoshi Tominaga; Kenji Takamori
Journal:  Acta Derm Venereol       Date:  2020-01-15       Impact factor: 3.875

7.  Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Authors:  Hatsue Fujino; Mio Tanaka; Michio Imamura; Kei Morio; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Tomokazu Kawaoka; Shoichi Takahashi; Daiki Miki; Masataka Tsuge; Akira Hiramatsu; Hiroshi Aikata; C Nelson Hayes; Kazuaki Chayama
Journal:  BMC Gastroenterol       Date:  2019-10-24       Impact factor: 3.067

8.  Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.

Authors:  Saadet Inan; Nae J Dun; Alan Cowan
Journal:  Molecules       Date:  2021-09-11       Impact factor: 4.411

Review 9.  Cholestatic pruritus: a knowledge update.

Authors:  Thaís Reginatto Nietsche; Gabriel Dotta; Carlos Baptista Barcaui; Maria Lúcia Cardoso Gomes Ferraz
Journal:  An Bras Dermatol       Date:  2022-03-09       Impact factor: 2.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.